Clinical Quality Measures for PQRS
<table>
<thead>
<tr>
<th>#</th>
<th>Domain</th>
<th>Measure Title/Description</th>
<th>Type</th>
<th>Denominator</th>
<th>Numerator</th>
<th>Denominator Exclusions/Exceptions</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>102</td>
<td>Efficiency and Cost Reduction</td>
<td>Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients: Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer</td>
<td>Process</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>Patients that have had prior treatment for prostate cancer</td>
<td>PQRS Measure – See Measure Title/Description</td>
</tr>
<tr>
<td>194</td>
<td>Effective Clinical Care</td>
<td>Oncology: Cancer Stage Documented: Percentage of patients, regardless of age, with a diagnosis of cancer who are seen in the ambulatory setting who have a baseline American Joint Committee on Cancer (AJCC) cancer stage or documentation that the cancer is metastatic in the medical record at least once during the 12 month reporting period</td>
<td>Process</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>Patients that have had prior treatment for prostate cancer</td>
<td>PQRS Measure – See Measure Title/Description</td>
</tr>
<tr>
<td>250</td>
<td>Effective Clinical Care</td>
<td>Radical Prostatectomy Pathology Reporting: Percentage of radical prostatectomy pathology reports that include the pT category, the pN category, the Gleason score and a statement about margin status</td>
<td>Process</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>Patients that have had prior treatment for prostate cancer</td>
<td>PQRS Measure – See Measure Title/Description</td>
</tr>
<tr>
<td>101</td>
<td>Effective Clinical Care</td>
<td>Prostate Cancer: Avoidance of Bone Scan for Staging Low Risk Prostate Cancer Patients: Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer</td>
<td>Process</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>Patients that have had prior treatment for prostate cancer</td>
<td>PQRS Measure – See Measure Title/Description</td>
</tr>
<tr>
<td>104</td>
<td>Effective Clinical Care</td>
<td>Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients: Percentage of patients, regardless of age, with a diagnosis of prostate cancer at high risk of recurrence receiving external beam radiotherapy to the prostate who were prescribed adjuvant hormonal therapy (GnRH agonist or antagonist)</td>
<td>Process</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>Patients that have had prior treatment for prostate cancer</td>
<td>PQRS Measure – See Measure Title/Description</td>
</tr>
<tr>
<td>194</td>
<td>Effective Clinical Care</td>
<td>Oncology: Cancer Stage Documented: Percentage of patients, regardless of age, with a diagnosis of cancer who are seen in the ambulatory setting who have a baseline American Joint Committee on Cancer (AJCC) cancer stage or documentation that the cancer is metastatic in the medical record at least once during the 12 month reporting period</td>
<td>Process</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>Patients that have had prior treatment for prostate cancer</td>
<td>PQRS Measure – See Measure Title/Description</td>
</tr>
<tr>
<td>250</td>
<td>Effective Clinical Care</td>
<td>Radical Prostatectomy Pathology Reporting: Percentage of radical prostatectomy pathology reports that include the pT category, the pN category, the Gleason score and a statement about margin status</td>
<td>Process</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>Patients that have had prior treatment for prostate cancer</td>
<td>PQRS Measure – See Measure Title/Description</td>
</tr>
<tr>
<td>101</td>
<td>Effective Clinical Care</td>
<td>Prostate Cancer: Avoidance of Bone Scan for Staging Low Risk Prostate Cancer Patients: Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer</td>
<td>Process</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>Patients that have had prior treatment for prostate cancer</td>
<td>PQRS Measure – See Measure Title/Description</td>
</tr>
<tr>
<td>104</td>
<td>Effective Clinical Care</td>
<td>Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients: Percentage of patients, regardless of age, with a diagnosis of prostate cancer at high risk of recurrence receiving external beam radiotherapy to the prostate who were prescribed adjuvant hormonal therapy (GnRH agonist or antagonist)</td>
<td>Process</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>Patients that have had prior treatment for prostate cancer</td>
<td>PQRS Measure – See Measure Title/Description</td>
</tr>
<tr>
<td>194</td>
<td>Effective Clinical Care</td>
<td>Oncology: Cancer Stage Documented: Percentage of patients, regardless of age, with a diagnosis of cancer who are seen in the ambulatory setting who have a baseline American Joint Committee on Cancer (AJCC) cancer stage or documentation that the cancer is metastatic in the medical record at least once during the 12 month reporting period</td>
<td>Process</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>Patients that have had prior treatment for prostate cancer</td>
<td>PQRS Measure – See Measure Title/Description</td>
</tr>
<tr>
<td>250</td>
<td>Effective Clinical Care</td>
<td>Radical Prostatectomy Pathology Reporting: Percentage of radical prostatectomy pathology reports that include the pT category, the pN category, the Gleason score and a statement about margin status</td>
<td>Process</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>Patients that have had prior treatment for prostate cancer</td>
<td>PQRS Measure – See Measure Title/Description</td>
</tr>
<tr>
<td>101</td>
<td>Effective Clinical Care</td>
<td>Prostate Cancer: Avoidance of Bone Scan for Staging Low Risk Prostate Cancer Patients: Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer</td>
<td>Process</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>Patients that have had prior treatment for prostate cancer</td>
<td>PQRS Measure – See Measure Title/Description</td>
</tr>
<tr>
<td>104</td>
<td>Effective Clinical Care</td>
<td>Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients: Percentage of patients, regardless of age, with a diagnosis of prostate cancer at high risk of recurrence receiving external beam radiotherapy to the prostate who were prescribed adjuvant hormonal therapy (GnRH agonist or antagonist)</td>
<td>Process</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>Patients that have had prior treatment for prostate cancer</td>
<td>PQRS Measure – See Measure Title/Description</td>
</tr>
<tr>
<td>194</td>
<td>Effective Clinical Care</td>
<td>Oncology: Cancer Stage Documented: Percentage of patients, regardless of age, with a diagnosis of cancer who are seen in the ambulatory setting who have a baseline American Joint Committee on Cancer (AJCC) cancer stage or documentation that the cancer is metastatic in the medical record at least once during the 12 month reporting period</td>
<td>Process</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>Patients that have had prior treatment for prostate cancer</td>
<td>PQRS Measure – See Measure Title/Description</td>
</tr>
<tr>
<td>250</td>
<td>Effective Clinical Care</td>
<td>Radical Prostatectomy Pathology Reporting: Percentage of radical prostatectomy pathology reports that include the pT category, the pN category, the Gleason score and a statement about margin status</td>
<td>Process</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>PQRS Measure – See Measure Title/Description</td>
<td>Patients that have had prior treatment for prostate cancer</td>
<td>PQRS Measure – See Measure Title/Description</td>
</tr>
</tbody>
</table>

**Notes:**
- **PQRS Measure** refers to the Performance and Quality Measures Program (PQRS) measure.
- **Denominator** refers to the number of patients meeting the specified criteria.
- **Numerator** refers to the number of patients meeting the specified criteria who also meet the specified outcome.
- **Denominator Exclusions/Exceptions** specify the conditions under which the denominator is not counted.
- **Rationale** describes the purpose or reasoning behind the measure.
Non-PQRS Measure #1 (MUSIC QCDR-1): Prostate Biopsy Antibiotic Compliance

**DESCRIPTION:**
Prostate Biopsy: Compliance with AUA best practices for antibiotic prophylaxis for transrectal ultrasound-guided (TRUS) biopsy

**DOMAIN:**
Patient safety

**NUMERATOR:**
# of biopsies where a compliant antibiotic regimen was given

**DENOMINATOR:**
# of prostate biopsies for patients aged 30 or older

**DENOMINATOR EXCLUSIONS:**
Excludes non-TRUS biopsies; biopsies performed in patients < 30 years of age; biopsies performed in patients that have had prior treatment for prostate cancer

**RATIONALE:**
Evidence-based care

Non-PQRS Measure # 2 (MUSIC QCDR-2): Unplanned Hospital Admissions within 30 days of TRUS Biopsy

**DESCRIPTION:**
Percentage of biopsies where patients aged 30 years and older had an unplanned hospital admission within 30 days of biopsy

**DOMAIN:**
Effective clinical care

**NUMERATOR:**
# of biopsies where a hospital admission resulted within 30 days of the procedure

**DENOMINATOR:**
# of prostate biopsies for patients aged 30 or older

**DENOMINATOR EXCLUSIONS:**
Excludes non-TRUS biopsies; biopsies performed in patients < 30 years of age; biopsies performed in patients that have had prior treatment for prostate cancer

**RATIONALE:**
Metric of safety of medical care
Non-PQRS Measure # 3 (MUSIC QCDR-3): Prostate Cancer: Avoidance of Overuse of CT Scan for Staging Low Risk Prostate Cancer Patients

**DESCRIPTION:**
Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer.

**DOMAIN:**
Efficiency and cost reduction

**NUMERATOR:**
# of low risk prostate cancer patients receiving brachytherapy, EBRT, RP, or cryotherapy who did not have a CT scan since diagnosis of prostate cancer.

**DENOMINATOR:**
# of low-risk prostate cancer patients 30 years or older receiving brachytherapy, EBRT, RP, or cryotherapy.

**DENOMINATOR EXCLUSIONS:**
Excludes prostate cancer patients < 30 years of age; prostate cancer patients receiving an alternate form of treatment from those specified; patients that have had prior treatment for prostate cancer.

**RATIONALE:**
Metric of appropriate resource utilization.

Non-PQRS Measure # 4 (MUSIC QCDR-4): Prostate Cancer: Proportion of Patients with Low-Risk Prostate Cancer Receiving Active Surveillance

**DESCRIPTION:**
Proportion of patients with low-risk prostate cancer receiving active surveillance.

**DOMAIN:**
Effective clinical care

**NUMERATOR:**
# of low-risk prostate cancer patients on active surveillance.

**DENOMINATOR:**
# of prostate biopsies for patients aged 30 or older.

**DENOMINATOR EXCLUSIONS:**
Excludes prostate cancer patients < 30 years of age; patients that have had prior treatment for prostate cancer.

**RATIONALE:**
Metric of patient-centered decision making.
Non-PQRS Measure # 5 (MUSIC QCDR-5): Prostate Cancer: Percentage of Prostate Cancer Cases with a Length of Stay > 2 Days

**DESCRIPTION:**
Percentage of radical prostatectomy cases with a length of stay > 2 days

**DOMAIN:**
Effective clinical care

**NUMERATOR:**
# of patients with a length of stay > 2 days after radical prostatectomy

**DENOMINATOR:**
# of patients aged 30 or older who underwent a radical prostatectomy as treatment for prostate cancer

**DENOMINATOR EXCLUSIONS:**
Excludes prostate cancer patients < 30 years of age; patients that have had prior treatment for prostate cancer

**RATIONALE:**
Metric of appropriate resource utilization

Non-PQRS Measure # 6 (MUSIC QCDR-6): Unplanned Hospital Readmission within 30 Days of Radical Prostatectomy

**DESCRIPTION:**
Percentage of patients aged 30 years and older who had an unplanned hospital readmission within 30 days of principal procedure

**DOMAIN:**
Effective clinical care

**NUMERATOR:**
# of radical prostatectomies where a hospital admission resulted within 30 days of the procedure

**DENOMINATOR:**
# of radical prostatectomies for patients aged 30 or older

**DENOMINATOR EXCLUSIONS:**
Excludes prostatectomies performed in patients < 30 years of age; patients that have had prior treatment for prostate cancer

**RATIONALE:**
Metric of safety of medical care